Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
Studies among people with multiple sclerosis (pwMS) receiving disease-modifying therapies
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …
(DMTs) have provided adequate evidence for an appraisal of COVID-19 vaccination policies …
Multiple sclerosis and SARS-CoV-2: has the interplay started?
G Bellucci, V Rinaldi, MC Buscarinu, R Reniè… - Frontiers in …, 2021 - frontiersin.org
Current knowledge on Multiple Sclerosis (MS) etiopathogenesis encompasses complex
interactions between the host's genetic background and several environmental factors that …
interactions between the host's genetic background and several environmental factors that …
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
Abstract Background Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20
therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies …
therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies …
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …
CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially …
A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia
Background Antibody-based strategies for COVID-19 have shown promise in prevention
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …
and treatment of early disease. COVID-19 convalescent plasma (CCP) has been widely …
[HTML][HTML] Safety of COVID-19 vaccines: spotlight on neurological complications
The COVID-19 pandemic has led to unprecedented demand on the global healthcare
system. Remarkably, at the end of 2021, COVID-19 vaccines received approvals for human …
system. Remarkably, at the end of 2021, COVID-19 vaccines received approvals for human …
[HTML][HTML] Immunogenicity, effectiveness, and safety of COVID-19 vaccines in rheumatic patients: an updated systematic review and meta-analysis
Background: Vaccination is one of the most important measures worldwide to halt the
spread of the corona virus disease 2019 (COVID-19). However, the efficacy and safety of …
spread of the corona virus disease 2019 (COVID-19). However, the efficacy and safety of …
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
TE Smith, M Madhavan, D Gratch, A Patel… - Multiple Sclerosis and …, 2022 - Elsevier
Background The risk of SARS-CoV-2 infection and severity with disease modifying therapies
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
(DMTs) in multiple sclerosis (MS) remains unclear, with some studies demonstrating …
[HTML][HTML] The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
Background Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for
autoimmune diseases such as multiple sclerosis. Their possible impact on development of …
autoimmune diseases such as multiple sclerosis. Their possible impact on development of …